Snowball logo
logo
1SXP

SCHOTT Pharma AG & Co. KGaA

1SXP F
23.40+0.15  (0.65%)
Estimate
P/E
26
EPS
0.9
Beta
0.981
Growth
Revenue, YoY
-1.51%
Net income, YoY
-18.68%
FCF, YoY
258.43%
Forecast
P/E (FWD)
21.9
EPS (FWD)
1.071
Dividends
Dividend yield
0.77%
Annual payout
0.18
Next ex. div date
February 4, 27
Payout
16.45%
Dividend growth streak
2 y
Div.rating
About the company
Ticker
1SXP
ISIN
Country
Other
Sector (GICS)
Other
SCHOTT Pharma AG & Co. KGaA develops, manufactures, and sells drug containment solutions and delivery systems for injectable drugs for pharma, biotech, and life science industries worldwide. The company offers syriQ, a glass syringe for vaccines; syriQ BioPure, a glass syringe for biologics; syriQ BioPure silicone-free, a prefillable and silicone-free glass syringe for biologics; SCHOTT TOPPAC, a polymer syringe; SCHOTT TOPPAC cosmetic, a polymer syringe for aesthetic treatments; SCHOTT TOPPAC freeze, a polymer syringe for deep-cold applications; SCHOTT TOPPAC sensitive, a polymer syringe for sensitive drugs; SCHOTT TOPPAC infuse, a polymer syringe for infusion therapy; SCHOTT TOPPAC unique, a polymer container; and SCHOTT TOPPAC cartridge. It also provides pharmaceutical glass cartridge, such as cartriQ for peptide and protein-based injectables; cartriQ Large Volume for large-volume injectables; Cartridges Double Chamber for lyophilized drugs; Cartridges Break Resistant; and TopLine and StandardLine cartridges and vials. In addition, the company offers pharmaceutical glass vial, including adaptiQ for injectables; EVERIC pure for unmatched drug stability; EVERIC freeze for deep-cold applications; EVERIC care for a pH range; EVERIC strong & smooth for the filling line performance; EVERIC smart; EVERIC plus for sensitive drug formulations; and EVERIC Iyo to avoid fogging for lyophilized drugs. Further, it provides pharmaceutical glass ampoule products, comprising Ampoules easyOPC for ampoule opening; Ampoules Anti-Counterfeiting for protection against drug counterfeiting; and StandardLine ampoules. It also provides containment and drug delivery, analytics, fill-and-finish, regulatory, and sustainability services. The company was founded in 1884 and is headquartered in Mainz, Germany. SCHOTT Pharma AG & Co. KGaA operates as a subsidiary of Schott Glaswerke Beteiligungs- Und Export Gmbh.

Frequently asked questions

What sector does SCHOTT Pharma AG & Co. KGaA (1SXP) operate in?

SCHOTT Pharma AG & Co. KGaA belongs to the Other sector and operates in the Medical Instruments & Supplies industry.

What is SCHOTT Pharma AG & Co. KGaA (1SXP) current stock price?

As of the latest data, SCHOTT Pharma AG & Co. KGaA stock price is €23.40, with a previous close of €23.25. SCHOTT Pharma AG & Co. KGaA gained €0.15 in the last trading session, representing a 0.65% increase.

What is SCHOTT Pharma AG & Co. KGaA (1SXP) current market capitalization?

SCHOTT Pharma AG & Co. KGaA market cap is approximately 3.52 billion.

What is SCHOTT Pharma AG & Co. KGaA (1SXP) Earnings Per Share (EPS)?

The trailing EPS is €0.90, and the forward EPS is €1.07.

What is SCHOTT Pharma AG & Co. KGaA (1SXP) Price-to-Earnings (P/E) ratio?

SCHOTT Pharma AG & Co. KGaA current P/E ratio is 26, with a forward P/E of 21.85.

Does SCHOTT Pharma AG & Co. KGaA (1SXP) pay dividends?

Yes. SCHOTT Pharma AG & Co. KGaA pays annual dividends with an annualized yield of 0.77% and an estimated annual payout of €0.18 per share.

When is the next ex-dividend date for SCHOTT Pharma AG & Co. KGaA (1SXP)?

The next ex-dividend date is scheduled for February 04, 2027.

How did SCHOTT Pharma AG & Co. KGaA (1SXP) perform in its most recent earnings report?

In the last report (June 30, 2026), SCHOTT Pharma AG & Co. KGaA posted an EPS surprise of 0% and a revenue surprise of 0.9%.

When is SCHOTT Pharma AG & Co. KGaA (1SXP) next earnings report?

SCHOTT Pharma AG & Co. KGaA is expected to release its next earnings report on September 30, 2026.

What is SCHOTT Pharma AG & Co. KGaA (1SXP) beta (volatility) score?

SCHOTT Pharma AG & Co. KGaA has a beta of 0.981, meaning its volatility is roughly in line with the market.